Idorsia Ltd
Clazosentan in Aneurysmal Subarachnoid Hemorrhage
- Conditions
- Interventions
- First Posted Date
- 2009-07-15
- Last Posted Date
- 2018-07-09
- Lead Sponsor
- Idorsia Pharmaceuticals Ltd.
- Target Recruit Count
- 577
- Registration Number
- NCT00940095
- Locations
- πΊπΈ
Stanford Hospital and Clinis, Stanford, California, United States
πΊπΈMassachusetts General Hospital, Boston, Massachusetts, United States
πΊπΈDuke University Medical Center, Durham, North Carolina, United States
Clazosentan in Reducing Vasospasm-related Morbidity and All-cause Mortality in Adult Patients With Aneurysmal Subarachnoid Hemorrhage Treated by Surgical Clipping
- Conditions
- Interventions
- First Posted Date
- 2007-11-14
- Last Posted Date
- 2020-02-17
- Lead Sponsor
- Idorsia Pharmaceuticals Ltd.
- Target Recruit Count
- 1157
- Registration Number
- NCT00558311
- Locations
- π©πͺ
Thechnical University-Klinikum rechts der Isar, Munich, Germany
πΊπΈState University of New York at Stony Brook-Health Sciences Center, Stony Brook, New York, United States
πΊπΈUniversity of Cincinnati-Department of Neurosurgery, Cincinnati, Ohio, United States
Tezosentan in Acute Heart Failure
- Conditions
- Interventions
- First Posted Date
- 2007-09-06
- Last Posted Date
- 2018-07-10
- Lead Sponsor
- Idorsia Pharmaceuticals Ltd.
- Target Recruit Count
- 735
- Registration Number
- NCT00525707
- Locations
- π¨π
Cardio Centro Ticino, Servizio Cardiovasculare, Lugano, Switzerland
π΅π±Kategra I Klinika Kardiolgii AM, Wroclaw, Poland
πΊπΈDenver VAMC, Denver, Colorado, United States
Tezosentan in the Treatment of Acute Heart Failure
- Conditions
- Interventions
- First Posted Date
- 2007-09-03
- Last Posted Date
- 2018-07-10
- Lead Sponsor
- Idorsia Pharmaceuticals Ltd.
- Target Recruit Count
- 713
- Registration Number
- NCT00524433
- Locations
- πΊπΈ
Oracle Research, Huntsville, Alabama, United States
πΊπΈUSC Medical Center, Los Angeles, California, United States
πΊπΈJacksonville Center for Clinical Research, Jacksonville, Florida, United States
Study of the Efficacy and Safety of Tezosentan in Patients With Pre-operative Pulmonary Hypertension, Due to Left Heart Disease, Undergoing Open Heart Surgery
- Conditions
- Interventions
- First Posted Date
- 2007-04-10
- Last Posted Date
- 2018-07-09
- Lead Sponsor
- Idorsia Pharmaceuticals Ltd.
- Target Recruit Count
- 274
- Registration Number
- NCT00458276
- Locations
- π¨π¦
University of Alberta Hospital, Edmonton, Alberta, Canada
π¨π¦London Health Sciences Centre-University Hospital, London, Ontario, Canada
πΊπΈColumbia University Medical Center, New York, New York, United States
Clazosentan in Preventing the Occurrence of Cerebral Vasospasm Following an Aneurysmal Subarachnoid Hemorrhage (aSAH)
- Conditions
- Interventions
- First Posted Date
- 2005-05-18
- Last Posted Date
- 2018-07-10
- Lead Sponsor
- Idorsia Pharmaceuticals Ltd.
- Target Recruit Count
- 413
- Registration Number
- NCT00111085
- Locations
- πΊπΈ
Dr. Aldrich, Baltimore, Maryland, United States
πΊπΈDr. Giuseppe Lanzino, Peoria, Illinois, United States
πΊπΈDr. Horner, Indianapolis, Indiana, United States